Skip to content
TrialScanner

NCT04606602

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Phase 1CompletedSLNLeadMEDPCollaborator

Registry record

Lead sponsor
Silence Therapeutics plc
Conditions
Hyperlipidemias; Dyslipidemias; Elevated Lp(a)
Primary completion
Aug 23, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04606602 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04606602: Study to Investigate Safety... | TrialScanner